China's drug regulator, the National Medical Products Administration (NMPA), has for the first time approved a novel medicine for commercial sale ahead of regulatory authorities in the United States, Japan, and Europe. This approval, announced on Tuesday, July 21, 2026, marks a "historic breakthrough" as China intensifies its focus on biopharmaceuticals as a key growth sector.

The therapy targets narcolepsy type 1, a lifelong brain disorder characterized by excessive daytime sleepiness and sudden muscle weakness triggered by strong emotions such as laughter or anger. The treatment is approved for patients aged 16 and older.

Although the drug's name was not disclosed, reports indicate it has received fast-track designation in the US and orphan-drug status in Japan and the European Union. Orphan-drug designation provides incentives like tax breaks and market exclusivity to encourage development of treatments for rare diseases.

Xu Xiaoqiang, head of chemical drugs registration at the NMPA, told state broadcaster CCTV that the drug was filed for approval in multiple countries but China was the first to grant approval. He emphasized that Chinese patients were included from the start in international clinical trials, enabling earlier regulatory clearance in China compared to other regions.

This milestone underscores China's expanding capabilities in globally developed, first-in-class drug innovation and its ambition to become a leader in the biopharmaceutical industry.

Sources